XNASQNRX
Market cap4mUSD
Dec 24, Last price
0.50USD
1D
-4.21%
1Q
-6.73%
Jan 2017
-99.93%
Name
Quoin Pharmaceuticals Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-90.02%
Rev. gr., 5y
%
Revenues
0k
Net income
-9m
L-6.37%
CFO
-8m
L-7.27%
Earnings
Mar 11, 2025
Profile
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 9,370 | 9,361 | 6,167 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,370) | (9,361) | (6,167) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 22 | (104) | (12,944) | ||||||
Tax Rate | |||||||||
NOPAT | (9,392) | (9,257) | 6,777 | ||||||
Net income | (8,687) -6.37% | (9,277) 8.91% | (8,519) 382.90% | ||||||
Dividends | (65,266) | ||||||||
Dividend yield | 11,380.02% | ||||||||
Proceeds from repurchase of equity | 5,834 | 10,110 | |||||||
BB yield | -132.02% | -1,682.34% | |||||||
| Debt | |||||||||
Debt current | 600 | 743,840 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 2,924 | 3,520 | 7,032,736 | ||||||
Net debt | (10,695) | (12,853) | 736,357 | ||||||
| Cash flow | |||||||||
Cash from operating activities | (7,864) | (8,481) | (5,720) | ||||||
CAPEX | (250) | (625) | |||||||
Cash from investing activities | 2,188 | (10,149) | (625) | ||||||
Cash from financing activities | 5,217 | 14,008 | 13,504 | ||||||
FCF | (9,392) | 1,741,357 | (1,748,348) | ||||||
| Balance | |||||||||
Cash | 10,695 | 12,854 | 7,483 | ||||||
Long term investments | |||||||||
Excess cash | 10,695 | 12,854 | 7,483 | ||||||
Stockholders' equity | (46,203) | 2,894,483 | (28,070) | ||||||
Invested Capital | 54,791 | (2,082) | 772,367 | ||||||
ROIC | 1.76% | ||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 901 | 404 | 26 | ||||||
Price | 4.91 245.42% | 1.42 -93.76% | 22.75 -78.94% | ||||||
Market cap | 4,419 670.51% | 574 -4.56% | 601 -72.21% | ||||||
EV | (6,276) | 2,919,721 | 736,958 | ||||||
EBITDA | (9,266) | (9,257) | (6,063) | ||||||
EV/EBITDA | 0.68 | ||||||||
Interest | 714 | 1,090 | |||||||
Interest/NOPBT | |||||||||